A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
NCT05646862 · Phase 3 · Recruiting
PHASEPhase 3
STATUSRecruiting
ENROLLMENT420
EST. COMPLETION2026-11-13
Conditions
Interventions
Study details
SPONSORHoffmann-La Roche
START DATE2023-06-07
Related company profiles
Primary source
Trial status and dates can change. Confirm enrollment and eligibility against the linked ClinicalTrials.gov record.
Evidence & limits
Source: Open the source record
- Record identifier
- NCT05646862
- Event / action date
- Not separately retained
- Source update date
- Not separately retained
- Platform retrieval / processing date
- Not separately retained
What it supports. Study information reported by the sponsor or investigator, including status, phase, enrollment, and recorded dates.
Limits. Registration or completion does not establish clinical success or approval. Sponsor-name associations can be ambiguous. Dates may be estimated; verify the live study record.
Connection basis. Company sponsor aliases and normalized lead-sponsor containment; the NCT identifier identifies the study.